Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising prostate cancer combo trial halted before results

NCT ID NCT01995058

Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested two drugs—cabozantinib and abiraterone—together in 54 men with castration-resistant prostate cancer that had spread to bones. The goal was to see if the combination could delay cancer growth. However, the study was stopped early by the sponsor for business reasons, so no effectiveness data were collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cabozantinib and abiraterone (with prednisone)
What this could lead to
If it had worked, this combination could have slowed cancer progression in men with advanced prostate cancer that has spread to bones.
What could go wrong
The trial was terminated early for business reasons, so no results are available. It is unclear if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

54 people

The number who actually took part.

Start date

Feb 2014

Finished

Nov 2014

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate. * Must be surgically or medically castrated (serum testosterone levels less than or equal to 50 ng/dL) * Must have castration-resistant prostate cancer (CRPC) with disease progression during LHRH therapy or after a surgical bilateral orchiectomy. * Bone metastasis related to prostate cancer * Adequate organ and marrow function * Capable of understanding and complying with the protocol requirements and signed the informed consent document * Sexually active subjects and their partners must agree to use medically accepted methods of barrier contraception (eg, male condom or female condom) as well as one other medically accepted method of contraception during the course of the study treatment and for 4 months after the last dose of study treatment. Exclusion Criteria: * Any prior treatment with abiraterone, enzalutamide, or any investigational agents blocking androgen receptor (AR) or androgen synthesis. * Any prior treatment with cabozantinib or participation in a prior clinical trial of cabozantinib. * Any prior cytotoxic therapy (including estramustine) or biologic therapy for the treatment of prostate cancer (a few exceptions will be allowed) * Any prior radionuclide therapy (eg, samarium 153, strontium 89, alpharadin) * Use of investigational agent within 28 days * Any pathological finding consistent with small cell carcinoma of the prostate * Known brain metastases or cranial epidural disease * Diagnosis of another malignancy within 2 years, except for superficial non-melanoma skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Castration-resistant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Castration-resistant prostate cancer Prostate cancer Prostatic neoplasms

Contacts and locations

Locations

  • Study site

    Scottsdale, Arizona, 85258, United States

  • Study site

    Sedona, Arizona, 86336, United States

  • Study site

    Tucson, Arizona, 85710, United States

  • Study site

    Oxnard, California, 93030, United States

  • Study site

    San Diego, California, 92108, United States

  • Study site

    Aurora, Colorado, 80012, United States

  • Study site

    Aurora, Colorado, 80045, United States

  • Study site

    Athens, Georgia, 30607, United States

  • Study site

    Atlanta, Georgia, 30318, United States

  • Study site

    Peoria, Illinois, 61615, United States

  • Study site

    Wichita, Kansas, 67214, United States

  • Study site

    Las Vegas, Nevada, 89148, United States

  • Study site

    Raleigh, North Carolina, 27607, United States

  • Study site

    Tualatin, Oregon, 97062, United States

  • Study site

    Charleston, South Carolina, 29414, United States

  • Study site

    Greenville, South Carolina, 29605, United States

  • Study site

    Myrtle Beach, South Carolina, 29572, United States

  • Study site

    Dallas, Texas, 75246, United States

  • Study site

    Houston, Texas, 77024, United States

  • Study site

    Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.